Developing next generation medicines
that will lead the fight against cancer & inflammation
- Rhizen Pharmaceuticals AG to present updated clinical data on its lead oncology assets – Tenalisib, a trivalent inhibitor of key oncogenic pathways in Breast Cancer and RP12146, a selective PARP1 trapping agent in advanced/metastatic solid tumors at ASCO 2023
- Rhizen Pharmaceuticals AG Announces Upcoming Data Presentations at ESMO 2022 for Its Clinical Stage Assets; Tenalisib in Locally Advanced/ Metastatic Breast Cancer and RP12146 in Multiple Solid Tumors. (PR)
- RP12146, safer, second generation PARP1 & 2 inhibitor enters dose expansion across solid tumors with promising early signs of differentiation
Relentless and innovative thinking that keeps our science
one step ahead, always!
OUR INFLAMMMATION-FOCUSSED ASSETS
The Rhizen Journey!
Our journey to be a leading biopharmaceutical company developing differentiated products through cutting-edge science and strategic partnerships started in 2008.
Novel programs targeting multiple hallmarks of cancer & inflammation
Assessing the safety and efficacy of our novel pipeline
Accumulated from dedicated research efforts for the last 12 years
We Are All In To Make It Possible
Proven and seasoned senior leadership team with expertise spanning the entire discovery-development-commercialization value chain
OUR PARTNERING STRATEGY
Flexible Global and Regional Approach
Progress in-house assets through clinical POC/Phase II and out-license to global partners for registration and commercialization across major markets
Explore co-development opportunities with assets that complement Rhizen programs